Pharming Group N.V.(PHAR)Earnings, Financials & Key Ratios
PHAR•NASDAQ
$12.00
$843M mkt cap·300.0× P/E·Price updated May 7, 2026
AboutPharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Show more
- Revenue$377M+26.9%
- EBITDA$31M+311.0%
- Net Income$3M+124.1%
- EPS (Diluted)0.04+123.5%
- Gross Margin87.9%-0.2%
- EBITDA Margin8.12%+223.8%
- Operating Margin5.13%+277.0%
- Net Margin0.76%+119.0%
- ROE1.15%+121.3%
- ROIC5.53%+359.7%
- Debt/Equity0.42-17.7%
- Interest Coverage0.91+3141.5%
PHAR Key Insights
Pharming Group N.V. (PHAR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 12.2%
✗Weaknesses
- ✗Profits declining 40.3% over 5 years
- ✗Thin 5Y average net margin of 1.4%
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PHAR Price & Volume
Pharming Group N.V. (PHAR) stock price & volume — 10-year historical chart
Loading chart...
PHAR Growth Metrics
Pharming Group N.V. (PHAR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years41.36%
5 Years12.19%
3 Years22.41%
TTM26.54%
Profit CAGR
10 Years-
5 Years-40.31%
3 Years-40.65%
TTM123.83%
EPS CAGR
10 Years-
5 Years-38.91%
3 Years-37%
TTM122.69%
Return on Capital
10 Years13.11%
5 Years2.2%
3 Years0.53%
Last Year5.45%
PHAR Recent Earnings
Pharming Group N.V. (PHAR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026EPS
$0.07
Est $0.05
-240.0%
Revenue
$72M
Est $92M
-21.3%
Q2 2026
Mar 12, 2026EPS
$0.07
Est $0.15
-53.3%
Revenue
$107M
Est $112M
-4.7%
Q4 2025
Nov 6, 2025EPS
$0.10
Est $0.05
+100.0%
Revenue
$97M
Est $98M
-0.9%
Q3 2025
Jul 31, 2025EPS
$0.06
Est $0.10
+160.0%
Revenue
$111M
Est $80M
+37.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.07vs $0.05-240.0% | $72Mvs $92M-21.3% |
| Q2 2026 | Mar 12, 2026 | $0.07vs $0.15-53.3% | $107Mvs $112M-4.7% |
| Q4 2025 | Nov 6, 2025 | $0.10vs $0.05+100.0% | $97Mvs $98M-0.9% |
| Q3 2025 | Jul 31, 2025 | $0.06vs $0.10+160.0% | $111Mvs $80M+37.9% |
Based on last 12 quarters of dataView full earnings history →
PHAR Peer Comparison
Pharming Group N.V. (PHAR) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LGND | 4.13B | 210.33 | -956.05 | 27.28% | 19.34% | 5.11% | 0.01 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BMRN | 10.41B | 54.12 | 30.07 | 12.87% | 8.29% | 4.41% | 0.11 |
Compare PHAR vs Peers
Pharming Group N.V. (PHAR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHAR Income Statement
Pharming Group N.V. (PHAR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 107.52M | 154.58M | 189.39M | 212.17M | 198.87M | 205.62M | 245.32M | 297.2M | 377.18M |
| Revenue Growth % | 544.06% | 43.77% | 22.52% | 12.03% | -6.27% | 3.39% | 19.3% | 21.15% | 26.91% |
| Cost of Goods Sold | 14.93M | 25.37M | 23.93M | 23.54M | 21.14M | 17.56M | 25.21M | 35.4M | 45.63M |
| COGS % of Revenue | 13.89% | 16.41% | 12.63% | 11.09% | 10.63% | 8.54% | 10.28% | 11.91% | 12.1% |
| Gross Profit | 92.59M▲ 0% | 129.2M▲ 39.5% | 165.46M▲ 28.1% | 188.63M▲ 14.0% | 177.73M▼ 5.8% | 188.06M▲ 5.8% | 220.1M▲ 17.0% | 261.8M▲ 18.9% | 331.56M▲ 26.6% |
| Gross Margin % | 86.11% | 83.59% | 87.37% | 88.91% | 89.37% | 91.46% | 89.72% | 88.09% | 87.9% |
| Gross Profit Growth % | 686.73% | 39.55% | 28.06% | 14.01% | -5.78% | 5.81% | 17.04% | 18.94% | 26.64% |
| Operating Expenses | 66.3M | 85.74M | 97.22M | 112.38M | 164.17M | 169.83M | 225.49M | 270.42M | 312.19M |
| OpEx % of Revenue | 61.66% | 55.47% | 51.33% | 52.97% | 82.55% | 82.59% | 91.92% | 90.99% | 82.77% |
| Selling, General & Admin | 44.86M | 53.49M | 55.88M | 65M | 48.13M | 68.85M | 87.5M | 99.22M | 247.78M |
| SG&A % of Revenue | 41.73% | 34.6% | 29.51% | 30.63% | 24.2% | 33.49% | 35.67% | 33.38% | 65.69% |
| Research & Development | 22.38M | 33.04M | 31.79M | 38.52M | 70.37M | 52.53M | 68.91M | 83.15M | 0 |
| R&D % of Revenue | 20.82% | 21.37% | 16.78% | 18.15% | 35.38% | 25.55% | 28.09% | 27.98% | - |
| Other Operating Expenses | -790K | -684K | 9.55M | 8.86M | 45.67M | 48.44M | 69.08M | 88.06M | 64.4M |
| Operating Income | 26.29M▲ 0% | 43.46M▲ 65.3% | 68.25M▲ 57.0% | 76.26M▲ 11.7% | 13.56M▼ 82.2% | 18.23M▲ 34.5% | -5.39M▼ 129.5% | -8.62M▼ 60.0% | 19.37M▲ 324.7% |
| Operating Margin % | 24.45% | 28.12% | 36.03% | 35.94% | 6.82% | 8.87% | -2.2% | -2.9% | 5.13% |
| Operating Income Growth % | 316.6% | 65.32% | 57.03% | 11.74% | -82.22% | 34.45% | -129.55% | -60.03% | 324.66% |
| EBITDA | 30.38M | 50.96M | 74.05M | 84.57M | 33.17M | 31.42M | 10.54M | 7.45M | 30.62M |
| EBITDA Margin % | 28.26% | 32.97% | 39.1% | 39.86% | 16.68% | 15.28% | 4.3% | 2.51% | 8.12% |
| EBITDA Growth % | 367.91% | 67.72% | 45.3% | 14.21% | -60.78% | -5.28% | -66.46% | -29.31% | 311% |
| D&A (Non-Cash Add-back) | 4.1M | 7.5M | 5.8M | 8.31M | 19.61M | 13.19M | 15.93M | 16.07M | 11.25M |
| EBIT | -80.43M | 17.35M | 65.66M | 50.04M | 29.17M | 20.34M | -6.05M | 245K | 19.37M |
| Net Interest Income | -56.53M | -16.35M | -12.22M | -9.59M | -6.12M | -5.27M | -2.44M | -3.02M | -18.75M |
| Interest Income | 3.6K | 20.59K | 1.13M | 713.62K | 52.92K | 85K | 3.53M | 5.72M | 2.56M |
| Interest Expense | 21.28M | 16.37M | 13.35M | 10.31M | 6.18M | 5.36M | 5.96M | 8.74M | 21.31M |
| Other Income/Expense | -129.09M | -37.01M | -15.94M | -32.16M | 9.52M | -3.25M | -6.63M | 129K | -6.49M |
| Pretax Income | -107.25M▲ 0% | 980.32K▲ 100.9% | 52.3M▲ 5235.4% | 44.09M▼ 15.7% | 23.08M▼ 47.7% | 14.99M▼ 35.1% | -12.01M▼ 180.1% | -8.49M▲ 29.3% | 12.88M▲ 251.7% |
| Pretax Margin % | -99.75% | 0.63% | 27.62% | 20.78% | 11.6% | 7.29% | -4.9% | -2.86% | 3.42% |
| Income Tax | -11.33M | -27.61M | 11.75M | 6.35M | 7.08M | 1.31M | -1.46M | 3.35M | 10.34M |
| Effective Tax Rate % | 10.56% | -2816.34% | 22.46% | 14.4% | 30.69% | 8.76% | 12.19% | -39.44% | 80.25% |
| Net Income | -95.92M▲ 0% | 28.59M▲ 129.8% | 40.56M▲ 41.9% | 37.75M▼ 6.9% | 16M▼ 57.6% | 13.67M▼ 14.5% | -10.55M▼ 177.1% | -11.84M▼ 12.3% | 2.86M▲ 124.1% |
| Net Margin % | -89.22% | 18.5% | 21.41% | 17.79% | 8.04% | 6.65% | -4.3% | -3.98% | 0.76% |
| Net Income Growth % | -420.12% | 129.8% | 41.86% | -6.93% | -57.62% | -14.52% | -177.14% | -12.26% | 124.14% |
| Net Income (Continuing) | -91.47M | 28.59M | 40.56M | 37.75M | 16M | 13.67M | -10.55M | -11.84M | 2.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.54▲ 0% | 0.35▲ 122.7% | 0.48▲ 37.1% | 0.47▼ 2.1% | 0.18▼ 61.7% | 0.16▼ 11.1% | -0.14▼ 187.5% | -0.17▼ 21.4% | 0.04▲ 123.5% |
| EPS Growth % | -340% | 122.73% | 37.14% | -2.08% | -61.7% | -11.11% | -187.5% | -21.43% | 123.53% |
| EPS (Basic) | -1.54 | 0.35 | 0.52 | 0.47 | 0.20 | 0.17 | -0.14 | -0.17 | 0.04 |
| Diluted Shares Outstanding | 62.55M | 81.69M | 84.19M | 80.98M | 87.64M | 84.28M | 65.7M | 68.92M | 71.32M |
| Basic Shares Outstanding | 62.55M | 81.69M | 84.19M | 79.88M | 87.64M | 82.54M | 65.7M | 68.92M | 71.32M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PHAR Balance Sheet
Pharming Group N.V. (PHAR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 105.87M | 132.05M | 119.44M | 215.47M | 249.44M | 277.5M | 316.34M | 278.44M | 299.38M |
| Cash & Short-Term Investments | 70.37M | 91.87M | 74.35M | 167.94M | 191.92M | 207.34M | 213.42M | 167.89M | 179.81M |
| Cash Only | 70.37M | 91.87M | 74.35M | 167.94M | 191.92M | 207.34M | 61.74M | 54.94M | 146.02M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 151.68M | 112.95M | 33.79M |
| Accounts Receivable | 12.22M | 18.3M | 28.86M | 19.25M | 27.59M | 25.33M | 42.62M | 50.17M | 54.69M |
| Days Sales Outstanding | 41.47 | 43.22 | 55.63 | 33.11 | 50.64 | 44.97 | 63.41 | 61.62 | 52.92 |
| Inventory | 22M | 19.81M | 16.22M | 17.32M | 27.31M | 42.33M | 56.76M | 55.72M | 64.88M |
| Days Inventory Outstanding | 537.72 | 284.94 | 247.47 | 268.55 | 471.49 | 879.68 | 821.73 | 574.57 | 519.04 |
| Other Current Assets | 1.29M | 1.81M | -2.28M | 7.67M | 227K | 213K | 0 | 0 | 1K |
| Total Non-Current Assets | 93.5M | 113.39M | 136.48M | 127.08M | 147.87M | 148.3M | 146.51M | 121.55M | 200.43M |
| Property, Plant & Equipment | 9.88M | 9.61M | 16.3M | 17.73M | 33.16M | 39.15M | 33.47M | 23.3M | 23.96M |
| Fixed Asset Turnover | 10.88x | 16.08x | 11.62x | 11.97x | 6.00x | 5.25x | 7.33x | 12.76x | 15.74x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 135.5M |
| Intangible Assets | 67.94M | 59.98M | 79.4M | 72.55M | 83.83M | 75.12M | 71.27M | 61.04M | 0 |
| Long-Term Investments | 2.75M | 2.29M | 6.18M | 5.83M | 8.65M | 9.73M | 10.4M | 4.23M | 9.87M |
| Other Non-Current Assets | 1.6M | 1.38M | 2.54M | 30.98M | 1.01M | 1.33M | 1.62M | 2.43M | 93.97K |
| Total Assets | 199.38M▲ 0% | 245.45M▲ 23.1% | 255.91M▲ 4.3% | 342.55M▲ 33.9% | 397.31M▲ 16.0% | 425.8M▲ 7.2% | 462.85M▲ 8.7% | 399.99M▼ 13.6% | 499.81M▲ 25.0% |
| Asset Turnover | 0.54x | 0.63x | 0.74x | 0.62x | 0.50x | 0.48x | 0.53x | 0.74x | 0.75x |
| Asset Growth % | 49.53% | 23.11% | 4.27% | 33.85% | 15.99% | 7.17% | 8.7% | -13.58% | 24.96% |
| Total Current Liabilities | 70.22M | 94.49M | 114.25M | 62.91M | 46.77M | 59.7M | 77.97M | 73.8M | 115.79M |
| Accounts Payable | 11.31M | 7.6M | 40.65M | 11.03M | 7.6M | 8.75M | 16.02M | 10.1M | 105.87M |
| Days Payables Outstanding | 276.57 | 109.3 | 620.02 | 170.99 | 131.19 | 181.92 | 231.95 | 104.17 | 846.9 |
| Short-Term Debt | 26.87M | 40.31M | 51.13M | 1.67M | 1.88M | 1.77M | 1.82M | 4.25M | 5.34M |
| Deferred Revenue (Current) | 964.56K | 915.12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 35.29M | 46.32M | -10.55M | 21.26M | 0 | 0 | 0 | 3.28M | 1.22M |
| Current Ratio | 1.51x | 1.40x | 1.05x | 3.43x | 5.33x | 4.65x | 4.06x | 3.77x | 2.59x |
| Quick Ratio | 1.19x | 1.19x | 0.90x | 3.15x | 4.75x | 3.94x | 3.33x | 3.02x | 2.03x |
| Cash Conversion Cycle | 302.62 | 218.86 | -316.92 | 130.67 | 390.93 | 742.73 | 653.18 | 532.02 | -274.94 |
| Total Non-Current Liabilities | 106.61M | 80.32M | 24.27M | 129.48M | 157.63M | 161.46M | 166.1M | 105.12M | 107.07M |
| Long-Term Debt | 70.98M | 42.63M | 0 | 122.57M | 139.01M | 131.62M | 136.6M | 78.15M | 92.72M |
| Capital Lease Obligations | 467.88K | 187.6K | 4.89M | 6.74M | 18.46M | 29.84M | 29.51M | 26.97M | 14.35M |
| Deferred Tax Liabilities | 0 | 99.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 33.4M | 36.74M | 19.38M | 173.54K | 165K | 0 | 0 | 0 | 0 |
| Total Liabilities | 176.82M | 174.81M | 138.53M | 192.39M | 204.4M | 221.16M | 244.07M | 178.92M | 222.79M |
| Total Debt | 97.53M | 83.42M | 58.2M | 132.58M | 161.76M | 166.69M | 171.54M | 112.31M | 115.78M |
| Net Debt | 27.16M | -8.44M | -16.15M | -35.36M | -30.16M | -40.65M | 109.8M | 57.37M | -30.25M |
| Debt / Equity | 4.32x | 1.18x | 0.50x | 0.88x | 0.84x | 0.81x | 0.78x | 0.51x | 0.42x |
| Debt / EBITDA | 3.21x | 1.64x | 0.79x | 1.57x | 4.88x | 5.31x | 16.28x | 15.08x | 3.78x |
| Net Debt / EBITDA | 0.89x | -0.17x | -0.22x | -0.42x | -0.91x | -1.29x | 10.42x | 7.70x | -0.99x |
| Interest Coverage | -3.78x | 1.06x | 4.92x | 4.85x | 4.72x | 3.80x | -1.01x | 0.03x | 0.91x |
| Total Equity | 22.56M▲ 0% | 70.64M▲ 213.2% | 117.39M▲ 66.2% | 150.16M▲ 27.9% | 192.92M▲ 28.5% | 204.64M▲ 6.1% | 218.78M▲ 6.9% | 221.06M▲ 1.0% | 277.02M▲ 25.3% |
| Equity Growth % | -21.91% | 213.15% | 66.18% | 27.92% | 28.47% | 6.08% | 6.91% | 1.04% | 25.31% |
| Book Value per Share | 0.36 | 0.86 | 1.39 | 1.85 | 2.20 | 2.43 | 3.33 | 3.21 | 3.88 |
| Total Shareholders' Equity | 22.56M | 70.64M | 117.39M | 150.16M | 192.92M | 204.64M | 218.78M | 221.06M | 277.02M |
| Common Stock | 6.95M | 7.11M | 7.23M | 5.99M | 7.43M | 7.51M | 7.67M | 7.77M | 8.01M |
| Retained Earnings | -427.42M | -381.65M | -340.71M | -221.85M | -273.17M | -256.43M | -265.26M | -275.49M | -272.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.13M | 1.88M | 8.93M | 0 | 3.4M | -8.74M | -2.06M | -209K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAR Cash Flow Statement
Pharming Group N.V. (PHAR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 45.84M | 46.19M | 74.15M | 83.63M | 37.84M | 22.46M | -17.3M | -1.79M | 50.07M |
| Operating CF Margin % | 42.64% | 29.88% | 39.15% | 39.41% | 19.03% | 10.92% | -7.05% | -0.6% | 13.27% |
| Operating CF Growth % | 535.73% | 0.75% | 60.54% | 12.78% | -54.75% | -40.65% | -177.04% | 89.63% | 2889.14% |
| Net Income | 26.29M | 43.46M | 52.3M | 44.09M | 23.08M | 14.99M | -12.01M | -8.49M | 2.86M |
| Depreciation & Amortization | 4.1M | 7.5M | 5.8M | 8.31M | 19.61M | 13.19M | 15.93M | 16.07M | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.54M | 9.06M | 6.39M | 9.25M | 11.25M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.13M | 1.22M | 13.87M | 28.6M | -8.94M | -11.72M | -13.51M | -10.55M | 32.8M |
| Working Capital Changes | 13.33M | -6M | 2.17M | -3.92M | -4.96M | -387K | -16.96M | -10.07M | 14.4M |
| Change in Receivables | 0 | 0 | -7.8M | -7.04M | 5.92M | 2.36M | -18.54M | -6.78M | -3.36M |
| Change in Inventory | -471.48K | 1.17M | 4.24M | -4.93M | -6.15M | -15.02M | -14.43M | -503K | -1.29M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.87M |
| Cash from Investing | -7.25M | -4.31M | -28.26M | -15.63M | -21.3M | 5.32M | -129.39M | 31.62M | 18.43M |
| Capital Expenditures | -7.25M | -4.31M | -25.45M | -15.3M | -16.72M | -1.98M | -1.46M | -796K | -757.1K |
| CapEx % of Revenue | 6.75% | 2.79% | 13.44% | 7.21% | 8.41% | 0.96% | 0.6% | 0.27% | 0.2% |
| Acquisitions | 0 | 0 | -2.81M | -329K | 0 | 7.3M | 0 | 0 | -65.53M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 1K | 0 | 0 | 0 | 21.28M | 0 | 84.72M |
| Cash from Financing | -3.91M | -20.55M | -63.47M | 60.69M | -27.95M | -4.98M | -1.04M | -34.41M | 14.48M |
| Debt Issued (Net) | 1.37M | -17.39M | -37.39M | 83.41M | -3.22M | -3.31M | -4.04M | -34.39M | 0 |
| Equity Issued (Net) | 0 | 12.01M | 3.11M | 2.79M | 4.72M | 2.28M | 0 | 0 | 19.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -4.62M | -12.57M | -29.19M | -25.51M | -29.45M | -3.95M | 3M | -19K | -5.39M |
| Net Change in Cash | 33.42M▲ 0% | 24.62M▼ 26.3% | -17.52M▼ 171.2% | 130.81M▲ 846.6% | -13.23M▼ 110.1% | 15.42M▲ 216.5% | -145.6M▼ 1044.4% | -6.8M▲ 95.3% | 91.09M▲ 1440.2% |
| Free Cash Flow | 38.59M▲ 0% | 41.87M▲ 8.5% | 48.7M▲ 16.3% | 68.33M▲ 40.3% | 21.13M▼ 69.1% | 20.48M▼ 3.1% | -18.77M▼ 191.6% | -2.59M▲ 86.2% | 49.31M▲ 2003.3% |
| FCF Margin % | 35.89% | 27.09% | 25.71% | 32.2% | 10.62% | 9.96% | -7.65% | -0.87% | 13.07% |
| FCF Growth % | 418.59% | 8.51% | 16.29% | 40.31% | -69.08% | -3.05% | -191.63% | 86.19% | 2003.28% |
| FCF per Share | 0.62 | 0.51 | 0.58 | 0.84 | 0.24 | 0.24 | -0.29 | -0.04 | 0.69 |
| FCF Conversion (FCF/Net Income) | -0.48x | 1.62x | 1.83x | 2.22x | 2.37x | 1.64x | 1.64x | 0.15x | 17.51x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAR Key Ratios
Pharming Group N.V. (PHAR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -67.12% | -372.93% | 61.36% | 43.14% | 28.22% | 9.33% | 6.88% | -4.98% | -5.38% | 1.15% |
| Return on Invested Capital (ROIC) | -24.26% | 34.01% | 58.25% | 62.64% | 52.95% | 7.33% | 8.37% | -1.64% | -2.13% | 5.53% |
| Gross Margin | 70.5% | 86.11% | 83.59% | 87.37% | 88.91% | 89.37% | 91.46% | 89.72% | 88.09% | 87.9% |
| Net Margin | -110.48% | -89.22% | 18.5% | 21.41% | 17.79% | 8.04% | 6.65% | -4.3% | -3.98% | 0.76% |
| Debt / Equity | 2.45x | 4.32x | 1.18x | 0.50x | 0.88x | 0.84x | 0.81x | 0.78x | 0.51x | 0.42x |
| Interest Coverage | -3.89x | -3.78x | 1.06x | 4.92x | 4.85x | 4.72x | 3.80x | -1.01x | 0.03x | 0.91x |
| FCF Conversion | 0.57x | -0.48x | 1.62x | 1.83x | 2.22x | 2.37x | 1.64x | 1.64x | 0.15x | 17.51x |
| Revenue Growth | 41.01% | 544.06% | 43.77% | 22.52% | 12.03% | -6.27% | 3.39% | 19.3% | 21.15% | 26.91% |
PHAR Frequently Asked Questions
Pharming Group N.V. (PHAR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pharming Group N.V. (PHAR) reported $376.0M in revenue for fiscal year 2025. This represents a 78283% increase from $0.5M in 2005.
Pharming Group N.V. (PHAR) grew revenue by 26.9% over the past year. This is strong growth.
Yes, Pharming Group N.V. (PHAR) is profitable, generating $2.8M in net income for fiscal year 2025 (0.8% net margin).
Dividend & Returns
Pharming Group N.V. (PHAR) has a return on equity (ROE) of 1.1%. This is below average, suggesting room for improvement.
Pharming Group N.V. (PHAR) generated $48.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More PHAR
Pharming Group N.V. (PHAR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates